Inaccurate Report of COVID-19 Vaccine Agreement

The report made by the Courier Mail and other media agencies today that an agreement has been struck to specifically secure s…

Rare Diseases in Asia-Pacific

Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-ava…

CSL’s Global Role in Battling COVID-19

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19 …

UQ COVID 19 Vaccine to Commence Human Trials

Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia

CSL Behring Begins Trial for Respiratory Distress

Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe res…

COVID-19 Update

CSL continues to provide medicines to patients around the world.

CSL Behring Gene Therapy Agreement with uniQure

Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits w…

CSL Behring Presents Results for Garadacimab

Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation